{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-035787","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.047700+00:00","generated_at":"2026-05-26T03:17:04.999015+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Madrigal Q4 2024 Rezdiffra sales $103.3M; new 2-year data shows benefit in F4c MASH cirrhosis","bullets":["Q4 and FY 2024 Rezdiffra net sales $103.3M and $180.1M; no product sales in prior year.","Over 11,800 patients on Rezdiffra at year-end 2024; cash and marketable securities $931.3M.","Two-year open-label data in compensated MASH cirrhosis (F4c): mean 6.7 kPa liver stiffness reduction (VCTE), statistically significant vs baseline.","51% of F4c patients achieved ≥25% reduction in liver stiffness; safety profile consistent with prior trials.","MAESTRO-NASH OUTCOMES trial fully enrolled (data anticipated 2027); CHMP opinion expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-035787","json":"https://secwatch.observer/filing/0001193125-25-035787.json","markdown":"https://secwatch.observer/filing/0001193125-25-035787.md","text":"https://secwatch.observer/filing/0001193125-25-035787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312525035787/0001193125-25-035787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312525035787/d924231d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:17:04.999015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}